152 related articles for article (PubMed ID: 29305171)
1. SUSD2 promotes cancer metastasis and confers cisplatin resistance in high grade serous ovarian cancer.
Xu Y; Miao C; Jin C; Qiu C; Li Y; Sun X; Gao M; Lu N; Kong B
Exp Cell Res; 2018 Feb; 363(2):160-170. PubMed ID: 29305171
[TBL] [Abstract][Full Text] [Related]
2. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
3. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.
Ma H; Li Y; Wang X; Wu H; Qi G; Li R; Yang N; Gao M; Yan S; Yuan C; Kong B
Cell Death Dis; 2019 Feb; 10(3):166. PubMed ID: 30778048
[TBL] [Abstract][Full Text] [Related]
4. CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression.
Xu Y; Zhang Q; Miao C; Dongol S; Li Y; Jin C; Dong R; Li Y; Yang X; Kong B
Cancer Med; 2019 Jan; 8(1):351-362. PubMed ID: 30565428
[TBL] [Abstract][Full Text] [Related]
5. NANOG regulates epithelial-mesenchymal transition and chemoresistance in ovarian cancer.
Qin S; Li Y; Cao X; Du J; Huang X
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 27884977
[TBL] [Abstract][Full Text] [Related]
6. Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease.
Haley J; Tomar S; Pulliam N; Xiong S; Perkins SM; Karpf AR; Mitra S; Nephew KP; Mitra AK
Oncotarget; 2016 May; 7(22):32810-20. PubMed ID: 27147568
[TBL] [Abstract][Full Text] [Related]
7. Sushi Domain Containing 2 (SUSD2) inhibits platelet activation and binding to high-grade serous ovarian carcinoma cells.
Lager TW; Roetman JJ; Kunkel J; Thacker M; Sheets JN; Egland KA; Miles CM; Larson MK; Gubbels JAA
Platelets; 2018 Dec; 29(8):834-837. PubMed ID: 30335544
[TBL] [Abstract][Full Text] [Related]
8. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.
Wu AY; Gu LY; Cang W; Cheng MX; Wang WJ; Di W; Huang L; Qiu LH
J Exp Clin Cancer Res; 2019 Apr; 38(1):176. PubMed ID: 31023317
[TBL] [Abstract][Full Text] [Related]
9. Human chorionic gonadotropin β regulates epithelial-mesenchymal transition and metastasis in human ovarian cancer.
Liu N; Peng SM; Zhan GX; Yu J; Wu WM; Gao H; Li XF; Guo XQ
Oncol Rep; 2017 Sep; 38(3):1464-1472. PubMed ID: 28713970
[TBL] [Abstract][Full Text] [Related]
10. High expression of SLC7A1 in high-grade serous ovarian cancer promotes tumor progression and is involved in MAPK/ERK pathway and EMT.
You S; Han X; Xu Y; Sui L; Song K; Yao Q
Cancer Med; 2024 May; 13(10):e7217. PubMed ID: 38752472
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.
Latifi A; Abubaker K; Castrechini N; Ward AC; Liongue C; Dobill F; Kumar J; Thompson EW; Quinn MA; Findlay JK; Ahmed N
J Cell Biochem; 2011 Oct; 112(10):2850-64. PubMed ID: 21618587
[TBL] [Abstract][Full Text] [Related]
12. ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.
Böpple K; Oren Y; Henry WS; Dong M; Weller S; Thiel J; Kleih M; Gaißler A; Zipperer D; Kopp HG; Aylon Y; Oren M; Essmann F; Liang C; Aulitzky WE
Cell Death Dis; 2024 Apr; 15(4):290. PubMed ID: 38658567
[TBL] [Abstract][Full Text] [Related]
13. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
[TBL] [Abstract][Full Text] [Related]
14. Epithelial‑mesenchymal transition induced by bone morphogenetic protein 9 hinders cisplatin efficacy in ovarian cancer cells.
Wang Y; Yang B; Zhao J; Yu X; Liu X; Zhang L; Zhang Y; Li X; Zhai Z
Mol Med Rep; 2019 Mar; 19(3):1501-1508. PubMed ID: 30628686
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol Contrasts LPA-Induced Ovarian Cancer Cell Migration and Platinum Resistance by Rescuing Hedgehog-Mediated Autophagy.
Ferraresi A; Esposito A; Girone C; Vallino L; Salwa A; Ghezzi I; Thongchot S; Vidoni C; Dhanasekaran DN; Isidoro C
Cells; 2021 Nov; 10(11):. PubMed ID: 34831435
[No Abstract] [Full Text] [Related]
16. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
17. NID1, a new regulator of EMT required for metastasis and chemoresistance of ovarian cancer cells.
Zhou Y; Zhu Y; Fan X; Zhang C; Wang Y; Zhang L; Zhang H; Wen T; Zhang K; Huo X; Jiang X; Bu Y; Zhang Y
Oncotarget; 2017 May; 8(20):33110-33121. PubMed ID: 28416770
[TBL] [Abstract][Full Text] [Related]
18.
Sheets JN; Patrick ME; Egland KA
Oncotarget; 2020 Jun; 11(24):2290-2301. PubMed ID: 32595828
[TBL] [Abstract][Full Text] [Related]
19. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]